Kristan Meetze

Kristan Meetze has a diverse work experience in the pharmaceutical and biotech industry. Kristan started their career as a Post-doctoral Scientist at ELI LILLY AND CO in 2000. Kristan then worked at Millennium Pharmaceuticals as a Senior Scientist I from 2002 to 2007. Kristan then joined AVEO Oncology, where they served as an Associate Director, Pharmacology and Preclinical Development from 2007 to 2012.

In 2013, Kristan joined Blend Therapeutics as the Head of Biology for a year. Kristan then moved to Siamab Therapeutics in 2014 as the Senior Director of Research and Development.

Kristan has also worked as a consultant in various companies. Kristan worked as a Cancer Pharmacology and Preclinical Development Consultant at NED BIOSCIENCES from 2016 to 2019. Kristan was a Preclinical Development and Tumor Biology Consultant at Adastra Pharmaceuticals from 2016 to 2021. Kristan served as a Cancer Pharmacology Consultant at Dracen Pharmaceuticals, Inc. from 2018 to 2020.

From 2017 to 2021, Kristan worked as a Program Management Consultant at Jounce Therapeutics, Inc. In 2019, they joined Cullinan Oncology as the Vice President of Preclinical and Early Development, and also worked as a Preclinical and Early Development Consultant until 2021.

Overall, Kristan Meetze has extensive experience in preclinical development, tumor biology, pharmacology, and program management in the pharmaceutical and biotech industry.

Kristan Meetze's education history includes studying Biochemistry at Susquehanna University to earn a B.S degree. After that, Kristan attended Wayne State University School of Medicine to pursue a Ph.D in Cancer Biology.